1. The effect of L-3,4-dihydroxyphenylalanine (=DOPA) on akinesia in parkinsonism;Birkmayer;Wiene Klin Wochenschr,1961
2. N-0923, a transdermal amino tetralin D2 dopamine agonist in the treatment of Parkinson's disease;Calabrese;Neurology,1997
3. Rationale for continuous dopaminomimetic therapy in Parkinson's disease;Chase;Neurology,1989
4. Impaired absorption of oral levodopa: A major cause for response fluctuations in Parkinson's disease;Djaldetti;Isr J Med Sci,1996
5. Preclinical pharmacology of ropinirole (SK&F 101468-A), a novel dopamine D2 agonist;Eden;Pharmacol Biochem Behav,1991